News & Press Releases
NEWS
Presentation of Saturn at PCR London Valve – November 2023
Our technology and transapical clinical results have been presented at 2023 PCR London Valve held on November 24-26 in Excel Center, London, UK. Specifically, Dr. Paolo Denti, MD held a presentation named "the Saturn TMVR Trans-apical FHU study: Two-year Trans-apical...
InnovHeart Featured in MedTech Strategist
We are pleased to announce that InnovHeart is featured in the MedTech Strategist October 2023 edition. The article "The Tantalizing Mitral Valve Device Market” by author Mary Stuart captures well InnovHeart’s commitment to enhancing the quality of life for millions of...
Presentation of Saturn at TVT – June 2023
View presentations on the novel SATURN TMVR technology with transseptal delivery, developed by Dr. Lauren S. Ranard in collaboration with Dr. Torsten Vahl, Dr. Paolo Denti, the staff from Skirball Center for Innovation, and InnovHeart R&D team, and presented at...
Presentation of Saturn at TCT – September 2022
Our technology has been presented at 2022 TCT held on September 16-19 in Boston, MA. Specifically, Dr. Paolo Denti, MD held a presentation about our Trans-apical FHU Study: 2-Years follow up, showing solid and effective data. Dr. Lauren S. Ranard, MD illustrated a...
Presentation of Saturn at TVT 2022 – June 2022
Our technology has been presented at 2022 TVT held on June 8-10 in Chicago, IL. Specifically, Dr. Paolo Denti, MD, spoke about "Trans-apical FHU Study: 1-Year follow up". Full video available here.
PRESS RELEASES
Transcatheter Mitral Valve Replacement Company InnovHeart Closes Series B Financing of €20 Million
InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announced today the closing of a €20 million round of equity financing. Founded in 2015 by Giovanni Righini, a 30-year veteran of...
InnovHeart Elects Keith D. Dawkins MD as Chairman of the Board
Dr. Dawkins is transitioning from his position as a member of the InnovHeart Board which he joined in May of this year. Dr. Dawkins has more than 35 years experience as both a practicing phys ician and an executive within the medical device industry. He currently also...
InnovHeart Appoints Keith D. Dawkins, M.D., as Board Member
InnovHeart s.r.l., a developer of novel transcatheter mitral valve replacement (TMVR) systems for the treatment of mitral valve disease, announces the appointment of veteran medical device executive Keith D. Dawkins, M.D., to a newly created position on its Board of Directors.